Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vitamin B5 in Adjuvant Treatment of IBD
NCT05701501Unknown
- Sponsor
- Changhai Hospital
- Start
- Feb 2023
- Primary completion
- Feb 2024
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Randomised, double-blind trial of Pantothenic acid in inflammatory bowel disease (IBD) (2 arms), sponsored by Changhai Hospital. Primary endpoint: Clinical remission rate at 12 months. Status: unknown.
02
Drugs
Pantothenic acid
03
Conditions
inflammatory bowel disease (IBD)
Beyond the preview
Go deeper on NCT05701501.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05701501.